STA
CAI

Summit Trail Advisors’s Caris Life Sciences CAI Stock Holding History

Summit Trail Advisors’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$343K Buy
19,248
+6,931
+56% +$124K ﹤0.01% 1317
2026
Q1 		$220K Buy
12,317
+3,025
+33% +$66.1K ﹤0.01% 1358
2025
Q4 		$251K Buy
+9,292
New +$262K ﹤0.01% 1237

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Summit Trail Advisors's CAI Position: Q2 2026 in Review

Summit Trail Advisors increased its Caris Life Sciences (CAI) stake by 56% in Q2 2026, buying an estimated $124K and bringing the position to 19,248 shares worth $343K. The position accounts for ﹤0.01% of the portfolio, ranked #1317.

Summit Trail Advisors first reported a position in CAI in Q4 2025 and has held it in 3 quarters since. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Summit Trail Advisors held 19,248 shares of Caris Life Sciences worth $343K as of Q2 2026.
  • Summit Trail Advisors bought 6,931 Caris Life Sciences shares in Q2 2026, an estimated $124K.
  • Caris Life Sciences made up ﹤0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1317 holding.
  • Summit Trail Advisors first reported a position in Caris Life Sciences in Q4 2025 and has held it in 3 quarters since.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.